Fig. 1: Trial profile. | Nature Communications

Fig. 1: Trial profile.

From: Efficacy, immunogenicity and safety of CoronaVac® in children and adolescents aged 6 months to 17 years: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial

Fig. 1

*Other: Vaccine group participants without corresponding control population. During the study period, CoronaVac® was approved for EUA (Emergency Use Authorization) in Chile for a population aged 3–17 years. Hence, participants aged 3–17 years in Chile (343 aged 6–17 years and 416 aged 3–5 years) were unblinded and administrated CoronaVac®. The data of these subjects were excluded from the efficacy analysis#. One participant, who was enrolled in the placebo group at the beginning of the study, had the first dose of placebo. However, this participant received CoronaVac® in the second injection. Thus, after the second dose, this participant was moved to the vaccine group in the safety analysis.

Back to article page